Universitätsklinikum Köln

Hospital


Location: Köln (Cologne), Germany (DE) DE

ISNI: 000000008852305X

ROR: https://ror.org/05mxhda18

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria (2022) Simon M, Gerlach R, Pfeifer Y, Pfennigwerth N, Gatermann SG, Schröder A, Hiergeist A, et al. Journal article Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry (2022) Blank N, Schmalzing M, Moinzadeh P, Oberste M, Siegert E, Mueller-Ladner U, Riemekasten G, et al. Journal article Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST) (2022) Sockel K, Frank S, Neu A, Ditschkowski M, Hilgendorf I, Goeckenjan M, Stoelzel F, et al. Conference contribution CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany (2022) Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Buecklein VL, Bonig H, et al. Conference contribution Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis (2022) Biedermann A, Mangelberger-Eberl D, Mougiakakos D, Büttner-Herold M, Flamann C, Kellner C, Altmeyer S, et al. Conference contribution Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection (2022) Buecklein VL, Perez-Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Conference contribution GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response (2022) Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, et al. Journal article Prevalence of sport injuries in Olympic combat sports: a cross-sectional study examining one Olympic period (2022) Lambert C, Ritzmann R, Lambert S, Lachmann D, Malliaropoulos NG, Gesslein M, Peters N, Shafizadeh S Journal article Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors (2022) Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Braegelmann J, Lohneis P, et al. Journal article